SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, today affirmed that the company is fully cooperating with the Joint Securities Crime Investigation Division of the Southern Seoul Prosecutors Office, over allegations that an employee sold shares recently using undisclosed information, which would constitute a violation of the law.
September 16, 2019
· 2 min read